Please login to order a test.
CYP2C9 is gene 9 within the C subfamily within the 2 family of the CYP450 superfamily. It metabolizes 5% of all prescribed drugs, such as glipizide, phenytoin, and warfarin. Genetic polymorphisms of CYP2C9 could be used to predict the altered enzyme activity and address the potential effects of metabolized drugs. Individuals exhibiting the most common variant alleles of 2C9, *2 or *3 are at increased risk of metabolizing a drug poorly or not at all. Deficient activity of 2C9 may result in reduced or lacking therapeutic benefit and an adverse drug reaction due to metabolite buildup in the body. This should be considered prior to initiating or modifying treatment or supplementing with additional drugs.
The metabolism of drugs is also influenced by ethnicity, diet, and other medications. All factors should be considered prior to initiating new therapy.
This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).
Real-time polymerase chain reaction (RT-PCR)
Whole blood or LabCorp buccal swab kit (buccal swab collection kit contains instructions for use of a buccal swab)
7 mL whole blood or LabCorp buccal swab kit
3 mL whole blood or two buccal swabs
Causes for Rejection
Frozen specimen; hemolysis; quantity not sufficient for analysis; improper container; one buccal swab; wet buccal swab